close
MENU
Hot Topic Hawke’s Bay
Hot Topic Hawke’s Bay
Shoeshine
5 mins to read

Homegrown pharmaceutical firm takes long view

ANALYSIS: Let Douglas Pharmaceuticals not be an outlier in New Zealand’s promising health tech sector.

Douglas Pharmaceuticals chief scientific officer Peter Surman talks about drug repurposing.

Maria Slade Mon, 19 Sep 2022

When the HPV (human papillomavirus) vaccine was introduced 15 years ago, women who have for decades endured the indignity of lying legs akimbo to undergo uncomfortable smear tests rejoiced as one.

While it may be too late for Shoeshine's more mature generation, younger women will benefit from a

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Contact the Writer: maria@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Homegrown pharmaceutical firm takes long view
Shoeshine,
95789
true